A Phase Ib study of epitinib to evaluate efficacy and safety in EGFR mutation positive (EGFRm+) NSCLC patients with brain metastasis (WCLC 2016)

 HMPL-813_Phase_Ib_WCLC_2016_thumb WCLC 2016: Epitinib in EGFRm+ NSCLC Patients with Brain Metastasis

A Phase Ib study of Epitinib to evaluate efficacy and safety in EGFR mutation positive (EGFRm+) NSCLC patients with brain metastasis

Qing Zhou1, Bin Gan1, Qunying Hong2, Mengzhao Wang3, XiaoQing Liu4, Liwei Yuan5, Ye Hua5, Hongcan Ren5, Weiguo Su5, Yi-Long Wu1

1Guangdong Lung Cancer Institute, Guangdong General Hospital (GGH) and Guangdong Academy of Medical Sciences, Guangzhou/China, 2Zhongshan Hospital, Shanghai Fudan University, Shanghai/China, 3Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing/China, 4307 Hospital, PLA, Beijing/China, 5Hutchison MediPharma Ltd, Shanghai/China

Conference: 17th World Conference on Lung Cancer
Abstract: #4253
1st Session: JCES01 Joint IASLC–Chinese Society for Clinical Oncology /   Chinese Alliance Against Lung Cancer Session (ID 413)
Date & Time:  Sunday, December 4,   2016 (10:30 AM – 11:30 AM)
2nd Session: 07. Advanced NSCLC P2.03b – Poster Session with Presenters   Present (ID 465)
Date & Time:  Tuesday, December 6,   2016 (2:30 PM – 3:45 PM)

Download Poster (PNG)